Skip to content
10-Q

Quarterly Report

PharmaCyte Biotech, Inc. PMCB

0001683168-25-006991

← back to feed
Filed
Sep 15, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Sep 12, 2025 6.8M sh
Shares Diluted Q1 2026 · Jul 31, 2025 6.8M sh
Shares Diluted Q1 2026 · Jul 31, 2024 7.87M sh
Stock Repurchased Q1 2026 · Jul 31, 2025 $0
Stock Repurchased Q1 2026 · Jul 31, 2024 $742.18K
Operating Cash Flow Q1 2026 · Jul 31, 2025 −$1.99M
Operating Cash Flow Q1 2026 · Jul 31, 2024 −$373.3K
Cash And Equivalents Q1 2026 · Jul 31, 2025 $13.18M
Cash And Equivalents Q1 2026 · Apr 30, 2025 $15.17M
Stockholders Equity Q1 2026 · Jul 31, 2025 $43.59M
Stockholders Equity Q1 2026 · Apr 30, 2025 $51.89M
Stockholders Equity Q1 2026 · Jul 31, 2024 $47.71M
Stockholders Equity Q1 2026 · Apr 30, 2024 $27.65M
Current Liabilities Q1 2026 · Jul 31, 2025 $1.06M
Current Liabilities Q1 2026 · Apr 30, 2025 $2.91M
Total Liabilities Q1 2026 · Jul 31, 2025 $1.52M
Total Liabilities Q1 2026 · Apr 30, 2025 $3.28M
Current Assets Q1 2026 · Jul 31, 2025 $19.11M
Current Assets Q1 2026 · Apr 30, 2025 $22.38M
Total Assets Q1 2026 · Jul 31, 2025 $45.11M
Total Assets Q1 2026 · Apr 30, 2025 $55.17M
Eps Diluted Q1 2026 · Jul 31, 2025 −$1.23
Eps Diluted Q1 2026 · Jul 31, 2024 $1.90
Eps Basic Q1 2026 · Jul 31, 2025 −$1.23
Eps Basic Q1 2026 · Jul 31, 2024 $1.90
Rd Expense Q1 2026 · Jul 31, 2025 $95.16K
Rd Expense Q1 2026 · Jul 31, 2024 $96.02K
Net Income Q1 2026 · Jul 31, 2025 −$8.36M
Net Income Q1 2026 · Jul 31, 2024 $23.42M
Operating Income Q1 2026 · Jul 31, 2025 −$848.31K
Operating Income Q1 2026 · Jul 31, 2024 −$1.27M
Revenue Q1 2026 · Jul 31, 2025 $0
Revenue Q1 2026 · Jul 31, 2024 $0